Laura Cortesi
University of Modena and Reggio Emilia
223 Papers
917 Citations
Laura Cortesi is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 30, co-authored 191 publications. Previous affiliations of Laura Cortesi include Mario Negri Institute for Pharmacological Research & Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.
Chat about Author
Papers
Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRIT Study): Interim Results
Francesco Sardanelli,Franca Podo,D'Agnolo G,Arduino Verdecchia,Mariano Santaquilani,Renato Musumeci,Giovanna Trecate,Siranoush Manoukian,Sandro Morassut,Clelia de Giacomi,Massimo Federico,Laura Cortesi,Stefano Corcione,Stefano Cirillo,Vincenzo Marra +14 more
TL;DR: Addition of MR imaging to the screening regimen for high-risk women may enable detection of otherwise unsuspected breast cancers.
Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study): Final Results
Francesco Sardanelli,Franca Podo,Filippo Santoro,Siranoush Manoukian,Bergonzi S,Giovanna Trecate,Daniele Vergnaghi,Massimo Federico,Laura Cortesi,Stefano Corcione,Sandro Morassut,Cosimo Di Maggio,Anna Cilotti,Laura Martincich,Massimo Calabrese,Chiara Zuiani,Lorenzo Preda,Bernardo Bonanni,Luca Alessandro Carbonaro,A. Contegiacomo,Pietro Panizza,Ernesto Di Cesare,Antonella Savarese,Marcello Crecco,Daniela Turchetti,Maura Tonutti,Paolo Belli,Alessandro Del Maschio +27 more
TL;DR: MRI largely outperformed mammography, ultrasonography, and their combination for screening high-risk women below and over 50, including those with previous personal breast cancer.
298
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
TL;DR: In this paper, the authors provide an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of breast cancer, including Olaparib and talazoparib.
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes
Angela Toss,Chiara Tomasello,Elisabetta Razzaboni,Giannina Contu,Giovanni Grandi,Angelo Cagnacci,Russell J. Schilder,Laura Cortesi +7 more
TL;DR: The identification of mutations in ovarian cancer susceptibility genes in healthy women may result in a more personalized cancer risk management with tailored clinical and radiological surveillance, chemopreventive approaches, and/or prophylactic surgeries.
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea Decensi,Matteo Puntoni,Aliana Guerrieri-Gonzaga,Silvia Caviglia,Franca Avino,Laura Cortesi,Cristiana Taverniti,Maria Grazia Pacquola,Fabio Falcini,Marcella Gulisano,Maria Digennaro,Anna Cariello,Katia Cagossi,Graziella Pinotti,Matteo Lazzeroni,Davide Serrano,Daniela Branchi,Sara Campora,Marilena Petrera,Tania Buttiron Webber,Luca Boni,Bernardo Bonanni +21 more
TL;DR: Tamoxifen at 5 mg/d for 3 years can halve the recurrence of breast intraepithelial neoplasia with a limited toxicity, which provides a new treatment option in these disorders.
187